Catalog #CP104
RecombiMAb anti-mouse CCR2 (CD192)
Clone
C2Mab-6-CP104
Reactivities
Mouse
Isotype
Mouse IgG2a, kappa
(switched from Rat IgG1, kappa)
(switched from Rat IgG1, kappa)
You may also be interested in:
Product Description
The C2Mab-6-CP104 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original C2Mab-6 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG1, κ to Mouse IgG2a, κ for use in murine models. Species-matched chimeric antibodies exhibit regulated effector functions—including Fc receptor binding and complement activation—and result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. This antibody has an effector function competent Fc domain allowing for activation of Fcγ receptors (FcγRs) to trigger antibody‑dependent cellular cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcγRIV, which is functionally similar to the FcγRIIIa receptor involved in human ADCC. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
C2Mab-6-CP104 reacts with mouse CC chemokine receptor type-2 (CCR2) also known as MCP-1 receptor and CD192. CCR2 is the primary receptor of C-C motif ligand 2 (CCL2) also known as monocyte chemoattractant protein-1 (MCP-1). CCR2 can also bind CCL7 and CCL12. CCR2 is a multi-pass transmembrane G protein-coupled receptor (GPCR) that is expressed on natural killer (NK) cells, macrophages, peripheral blood monocytes, and activated T cells, B cells, and immature dendritic cells (DCs). CCL2-CCR2 signaling is involved in the regulation of immune cells’ chemotaxis/migration, and during microbial infections, CCR2-positive macrophages and neutrophils drive innate immune responses. In neurobiology, CCR2 plays an important role in mediating peripheral nerve injury-induced neuropathic pain and facilitates the recruitment of macrophages/monocytes to the injury site following cerebral injury. The crosstalk between CCR2 on tumor-infiltrating immune and stromal cells and CCL2 on tumor cells is known to influence tumor growth, angiogenesis, and metastasis. CCR2 antagonists are often studied in relation to unwanted immune responses in inflammatory and autoimmune diseases, immunomodulation of the tumor microenvironment (TME) for enhancing anti-tumor immunity, and Treg function.
C2Mab-6-CP104 reacts with mouse CC chemokine receptor type-2 (CCR2) also known as MCP-1 receptor and CD192. CCR2 is the primary receptor of C-C motif ligand 2 (CCL2) also known as monocyte chemoattractant protein-1 (MCP-1). CCR2 can also bind CCL7 and CCL12. CCR2 is a multi-pass transmembrane G protein-coupled receptor (GPCR) that is expressed on natural killer (NK) cells, macrophages, peripheral blood monocytes, and activated T cells, B cells, and immature dendritic cells (DCs). CCL2-CCR2 signaling is involved in the regulation of immune cells’ chemotaxis/migration, and during microbial infections, CCR2-positive macrophages and neutrophils drive innate immune responses. In neurobiology, CCR2 plays an important role in mediating peripheral nerve injury-induced neuropathic pain and facilitates the recruitment of macrophages/monocytes to the injury site following cerebral injury. The crosstalk between CCR2 on tumor-infiltrating immune and stromal cells and CCL2 on tumor cells is known to influence tumor growth, angiogenesis, and metastasis. CCR2 antagonists are often studied in relation to unwanted immune responses in inflammatory and autoimmune diseases, immunomodulation of the tumor microenvironment (TME) for enhancing anti-tumor immunity, and Treg function.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 8.0 Dilution Buffer |
| Immunogen | Three KLH-conjugated synthetic peptides corresponding to the N-terminal sequence of mouse CCR2 |
| Reported Applications |
Flow cytometry ELISA For details on in vivo applications please contact technicalservice@bioxcell.com |
| Formulation |
PBS, pH 8.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation* |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein G |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
* Additional quality control measures for our InVivoPlus™ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlus™ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlus™ difference here.